ScreenerHero

BNR Burning Rock Biotech Limited

NAS · US · Healthcare · Diagnostics & Research · brbiotech.com
15.18USD-5.77%Mkt Cap: 160.09M $P/E: —

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, an…

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7

Key Statistics

Company
Market Cap160.09M USD
Enterprise Value-196.74M USD
Revenue (TTM)500.64M USD
Gross Profit402.91M USD
Net Income (TTM)-55.35M USD
Revenue/Share47.26 USD
Last Price15.18 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees667
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-27.78
PEG—
EV/EBITDA3.38
EV/Revenue-0.39
P/S0.34
P/B2.36
EPS (TTM)-0.85
EPS (Forward)-0.58
52W Range
6.79024% of range41.72
52W High41.72 USD
52W Low6.790 USD
Profitability
Gross Margin74.67%
Oper. Margin-13.36%
EBITDA Margin-11.64%
Profit Margin-10.26%
ROE-10.34%
ROA-6.75%
Growth
Revenue Growth-9.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.44M USD
CapEx (TTM)5.25M USD
FCF Margin2.59%
FCF Yield8.11%
Net Debt-371.71M USD
Net Debt/EBITDA6.38
Balance Sheet
Debt/Equity0.08
Current Ratio3.05
Quick Ratio2.75
Book Value/Sh6.82 USD
Cash/Share38.38 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMay 15, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.81M
Float3.42M
Insiders213.50%
Institutions47.19%
Short Interest
Short Ratio0.8d
Short % Float0.55%
Short % Out.0.37%
Shares Short39.41K
Short (prev mo.)39.45K
Technical
SMA 5011.65 (+30.3%)
SMA 20017.20 (-11.7%)
Beta1.29
S&P 52W Chg16.45%
Avg Vol (30d)51.19K
Avg Vol (10d)48.18K
Technical Indicators
RSI (14)53.5
MACD1.4249
MACD Signal1.6608
MACD Hist.-0.2359
BB Upper20.21 USD
BB Middle15.03 USD
BB Lower9.847 USD
BB Width68.94%
ATR (14)1.570 USD
Vol Ratio (20d)0.16x